New hope for rare blood cancers: drug trial aims to shrink spleens and ease suffering
NCT ID NCT05177211
Summary
This study is testing if the drug fedratinib is effective and safe for people with rare, hard-to-treat blood cancers. It will involve about 25 adults with specific conditions like MDS/MPN or chronic neutrophilic leukemia. The main goal is to see if the drug can control the disease and reduce symptoms like fatigue and pain over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.